HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms
StockNews.AI · 487 days
High Materiality8/10
AI Summary
HUTCHMED's ORPATHYS® remains in China's NRDL from January 2025. The drug targets MET exon 14 alterations in NSCLC patients. China has 95% medical insurance coverage, improving drug affordability. ORPATHYS® is the first selective MET inhibitor approved in China. The drug is jointly developed with AstraZeneca for multiple cancer types.
Sentiment Rationale
Continued inclusion in the NRDL boosts potential sales, echoing previous growth from approvals.
Trading Thesis
The drug’s established presence in the NRDL supports sustained long-term revenue.
Market-Moving
- HUTCHMED's ORPATHYS® remains in China's NRDL from January 2025.
- The drug targets MET exon 14 alterations in NSCLC patients.
- China has 95% medical insurance coverage, improving drug affordability.
Key Facts
- HUTCHMED's ORPATHYS® remains in China's NRDL from January 2025.
- The drug targets MET exon 14 alterations in NSCLC patients.
- China has 95% medical insurance coverage, improving drug affordability.
- ORPATHYS® is the first selective MET inhibitor approved in China.
- The drug is jointly developed with AstraZeneca for multiple cancer types.
Companies Mentioned
- AZN (AZN)
Corporate Developments
The article signifies a key milestone for a core product, directly impacting HCM.